Dental Procedures: ViziLite Plus Oral Exams

Examining the oral cavity using the Vizilite light stick.

Oral Lesions shown with ViziLite
Applying the TBlue630 marking system to lesions visible under ViziLite illumination.

ViziLite Cancer Screens

Oral Cancer Screening
We now know that oral cancer claims one life every hour in the U.S. - more than the number of lives lost to skin cancer, cervical cancer or Hodgkin's disease. Alarmingly, more than 25% of oral cancer victims have no lifestyle risk factors.

Because early detection is the key to successful outcomes, Comfort Dental at Creekside Commons has incorporated ViziLite Plus, a technology cleared by the FDA, into our standard of care, to ensure that you receive the most comprehensive oral cancer screening possible.

What is ViziLite Plus?
ViziLite Plus is a simple, painless and non-invasive technology that improves our ability to visualize, mark, evaluate and monitor suspicious areas at their earliest stages, before they can progress to something far more serious, and potentially life-threatening. ViziLite Plus helps us see what can't be seen with the unaided eye.

Dr. Cimaglio offers his patients age 18 and older comprehensive oral cancer exams with ViziLite Plus, the most advanced technology for the early detection of oral abnormalities, including pre-cancerous lesions and oral cancer. By performing annual ViziLite Plus exams in conjunction with a conventional head and neck examination, Dr. Cimalgio provides his patients with the most comprehensive oral cancer screening program available. Contact the office to schedule a ViziLite Plus exam today.

About ViziLite Plus
The newest tool in the fight against oral disease is the ViziLite Plus oral lesion identification and marking system.

ViziLite Plus, from Zila Pharmaceuticals, combines the oral screening technology of ViziLite, an advanced chemiluminescent light technology to help detect oral abnormalities, with TBlue630". TBlue630 is the only patented pharmaceutical-grade form of toluidine blue that has been cleared by the FDA for use in marking lesions identified during a ViziLite examination.

ViziLite Plus makes oral screening more comprehensive than ever before and is indicated for use in individuals at increased risk of oral cancer. If ViziLite reveals an abnormality, TBlue630 can be used to mark suspicious lesions for further evaluation.

For more information about ViziLite Plus, please visit www.vizilite.com.